Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q2 2019 · 10-Q
Revenue$7.88M$7.88M−80.3% vs Q2 2018 Net Income-$1.46M-$1.46MN/M vs Q2 2018 EPS Diluted-$0.04-$0.04N/M vs Q2 2018 Operating Income-$36,872,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$29,304,000N/M Margins · derivedOperating margin-467.9%−483.7 pt vs Q2 2018
Net margin-18.5%−45.0 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 7, 2019 · 38 d after period end